Summary. The effect of prolonged treatment with acarbose, an inhibitor of c~-glycosidase, has been studied in mice made obese and hyperinsulinaemic by goldthioglucose. After the onset of obesity, one month after goldthioglucose administration, mice were then treated, with or without a 10% sucrose supplement, for four months with acarbose, added to the diet at 50 mg/100 g food. When mice received a standard diet, acarbose had no effect on body weight, blood glucose or insulin levels. In contrast, in the control obese mice receiving a 10% sucrose-enriched diet, it decreased the body weight gain, and prevented the rise in glycaemia and insulinaemia. Basal (non insulin-stimulated) glucose uptake, which is decreased in isolated soleus muscle from untreated obese mice, returned to normal values under acarbose treatment. However, muscle insulin resistance was not improved in acarbosetreated obese mice at maximal and submaximal effective concentrations, despite a higher insulin binding in muscles of acarbose-treated obese than in control obese animals. Furthermore, insulin receptor autophosphorylation and tyrosine kinase activity were altered similarly in treated and untreated obese mice compared to lean mice.
Human and animal obesities are usually associated with insulin resistance, which in vivo is characterized by hyperinsulinaemia and normo-or hyperglycaemia [1, 2] . Insulin resistance is also present in vitro, in insulin target tissues such as skeletal muscle [3] [4] [5] [6] or adipocytes [7] . In the muscle of obese animals and humans, this resistance results from different abnormalities both at the level of insulin receptor, i.e. decreased receptor number [3, 8] and altered receptor tyrosine kinase activity [8, 9] , and at steps independent from the receptor, such as glucose and amino acid uptake or glycogen synthase activation [3, 4, 6, 10] .
Acarbose is a competitive inhibitor of intestinal c~-glycosidase and thus inhibits starch and sucrose digestion at the level of the small intestine [11, 12] . The unabsorbed carbohydrates are subsequently degraded by microorganisms in the large bowel. This leads to a decrease in the postprandial rise of blood glucose and, consequently, to a decreased insulin secretion. In genetically obese animals (fa/fa rats or db/db mice), treatment with acarbose was able to prevent hyperglycaemia and to decrease insulin levels. It also diminished the prevalence of diabetic nephropathy in acarbose-treated db/db mice [12] [13] [14] [15] . Hyperinsulinaemia plays a key role not only in the development of the obese syndrome, since it promotes adipose and liver lipogenesis, but also in the establishment and maintenance of insulin resistance [4] . The use of a model of experimentally-induced obesity makes it possible to perform longitudinal studies on the development of obesity and on the effect of treatment before obesity has plateaued. Taking advantage of the potential lowering effect of acarbose on insulinaemia, the present work was undertaken to study the effects of prolonged o~-glycosidase inhibition on the development of the obese syndrome, and on the state of insulin resistance in skeletal muscle [4] .
Materials and methods

Materials
Acarbose was a gift of Bayer laboratories (Wttppertal, FRG). Insulin (monocomponent) was purchased from Novo (Copenhagen, Denmark); Triton X-100, N-acetylglucosamine, goldthioglucose, and defatted bovine serum albumin were from Sigma Chemicals (St.Louis, Mo, USA). Wheat germ-agglutinin-agarose was from Miles Scientific. [7-32p ]ATP (triethylammonium salt; aqueous solution, 3,000 Ci/mmol) was from the Radiochemical Centre (Amersham, Bucks, UK). 1-[~4C]-deoxyglucose was from New England Nuclear (Dreich, FRG) and ~z~I was from Commissariat ~t l'6nergie atomique (Paris, France). All reagents for sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) were from BioRad Laboratories (Richmond, Calif, USA). Serum from patients B5 or B7 with autoantibodies to insulin receptors was a gift from Dr R Gorden (Bethesda, Md, USA) and photoreactive insulin (Bz-[2nitro, 4azidophenylacetyl] desPhe Blinsulin) was from Dr D. Brandenburg (Aachen, FRG). ( > 0.3 g/day). They were then divided in a control group, which received chow without drug (which will be referred to as "control obese") and a treated group receiving chow containing acarbose ("acarbose-treated obese") for a period of four months. Animals were weighed weekly. In some experiments, age-matched lean mice, which received the sucrose supplemented diet, were also used. At least 30 mice were included in each experimental group and all the experiments were repeated with two-four different groups.
Blood determinations
Monthly blood samplings (100 p.1) were performed between 10.00 and 12.00 hours from the retroorbital sinus under diethylether anaesthesia, and plasma stored at -20 ~ C. Plasma glucose and immunoreactive insulin were then determined as previously described [3, 16] . 
Animals
Male Swiss albino mice were fed ad libitum and maintained at 22 ~ C on a 12 h light cycle until the time of death. They were rendered obese by goldthioglucose (GTG) injection at 3 weeks of age [16] . The composition of the laboratory chow (Us• d'Alimentation Rationelle, Villemoisson, Epinay/Orge, France) was as follows (% weight): protein 22%, lipids 5%, starch 30%, hem• cellulose and other carbohydrates 25%, salts 6%, water 12% (3000 cal/kg food). Where indicated, food was supplemented with 10% sucrose. Acarbose (50 mg/100 g food) was added and thoroughly mixed with the powdered mouse chow before it was reconstituted into pellets.
Experimental protocol
Mice received goldthioglucose at 3 weeks of age [3, 16] and were then weighed twice weekly. Since goldthioglucose treatment does not produce obesity in all injected mice, "preobese" mice were selected at 8 weeks of age on the basis of their body weight gain
Deoxyglucose uptake and insulin binding to isolated soleus muscles
Soleus muscles were isolated and incubated as described previously [3, 5] . One soleus muscle was preincubated for 60 min at 37 ~ C in i ml Krebs-Ringer bicarbonate buffer (pH 7.35), containing 10 mg defatted bovine serum albumin, 2 mmol/1 pyruvate, in the absence or presence of insulin at the concentration indicated in the figures. Deoxyglucose uptake was then measured after a 15 min incubation with 2-deoxy-D-[1-14C]-glucose (0.5 mmol/1, 0.1 btCi/ml). At the end of incubation, muscles were washed, dissolved in 0.3 ml of i mol/1NaOH, and an aliquot sample used for determination of 14C content [3] . Insulin binding was measured after a 4 h incubation at 20 ~ C as previously described [3] .
Preparation of partially purified insulin receptors and measurement of insulin binding
Muscles (5 g) from hindlegs were dissected and used for preparation of partially purified insulin receptors [9, 17, 18] . Aliquot samples (10g l) of receptor preparations were incubated in Hepes (50 mmol/1), NaC1 (150 mmol/1) buffer pH 7.6 containing lZSf-labelled insulin (10-11 tool/l, 250 mCi/mg) in the absence or presence Acarbose treatment (day)
of unlabelled insulin (10-6 mol/1) in a final volume of 200 gl. After 2 h at 20 ~ C, bound insulin was separated from unbound hormone using polyethylene glycol [19] and the radioactivity of the pellet measured in a gamma spectrometer. To minimize interexperimental variations, the receptor preparations to be compared were always assayed in parallel, wheat germ agglutinin (WGA) -columns were identical, insulin binding was measured in the same assay and phosphorylation was carried out on the same day [20] . tions. After 30 min the reaction was stopped by applying 75 gl samples to filter papers (Whatman ET 31) and soaking the papers in a solution of 10% trichloracetic acid, and 10 mmol/1 sodium pyrophosphate. After extensive washing, radioactivity of the trichloracetic precipitable material adsorbed on papers was measured using Cerenkov radiation [9, 23] .
Cell-free phosphorylation and immunoprecipitation of partially purified insulin receptors
Statistical analysis
Statistical significance was assessed by Student's t-test for unpaired comparisons [24] .
To evaluate, on the same gel, both the 13-subunit receptor phosphorylation and insulin binding to the a-subunit, the receptor subunits were labelled according to their functions [9, 20] . Receptors were first labelled on the c~-subunit using photoreactive insulin. After incubation in the dark for 3 h at 15 ~ C with 5 nmol/1 12SI-labelled B2-Napa-insulin [21] , samples were irradiated for 5 min at 4 ~ C using a mercury lamp. The receptors were then used in a cell-free phosphorylation system [9, 20] in order to label the ~-subunit. Finally, the receptors were immunoprecipitated with antibodies against the insulin receptor and analysed by one dimensional SDS/7.5% PAGE according to Laemmli [22] . The gels were stained, dried, and autoradiographed. The labelled bands were cut and their radioactivity determined for lasI (c~-subunit) and 32p radioactivity (13-subunit).
Determination of insulin receptor kinase activity using a synthetic substrate
Partially purified insulin receptor preparations (30 gl) were preincubated for 60 min at 20 ~ C in 140 ~tl Hepes buffer (50 mmol/1, pH 7.6), containing NaC1 (150 mmol/1), bovine serum albumin (0.2 mg/ml) and insulin (10 -11 tool/1 to 10 7 mol/1). 
Results
Effect of acarbose treatment on body weight, glycaemia and insulinaemia of obese mice
As shown in Figure 1 , upper panel, acarbose treatment had no effect on body weight of goldthioglucose obese mice when normal food was given to the animals. By con- trast, when food was supplemented with 10% sucrose, acarbose prevented the additional body weight gain due to sucrose (Figure 1 , lower panel, Table 1 ). Acarbose was affecting body weight change mainly during the first month, the body weight gain being similar in control and treated groups during the second, third and fourth months of treatment (Table 1 ). This reduction in body weight gain was observed without any change in food intake ( Table 2) . Blood glucose and insulin determinations were perforlned monthly in the same groups of mice. When mice received the normal diet, acarbo~e did not modify glucose levels (Fig. 2 a) but delayed sligfftly the increase in insulin levels which occurred in control obese mice (Fig. 2  b) . However, it was no longer effective after three months of treatment. When food was supplemented with 10% sucrose, acarbose prevented the rise in blood glucose (Fig. 2 c) and the huge increase in insulin levels (Fig. 2 d) which were observed in control obese mice. Insulin levels were thus similar, at approximately 15 ng/ml, in acarbosetreated obese mice, whether they received the normal food or the diet enriched in sucrose. The insulin lowering effect of acarbose is even more evident when individual insulin levels are presented (Fig.3) . In the control obese group, all animals had insulin levels higher than the normal range (which is indicated by the shaded area), half of the animals having insulin levels higher than 30 ng/ml. By contrast, when animals received acarbose, one third of the animals had insulin levels in the normal range, and 90% of the animals presented levels lower than 20 ng/ml. It should be noted that a small percentage of obese mice seemed totally resistant to the treatment, insulin levels remaining higher than 25 ng/ml.
Effect of acarbose treatment on glucose uptake and insulin binding in isolated soleus muscle
Since acarbose was effective only when the food was supplemented with 10% sucrose, the following series of experiments were performed in mice receiving this diet. An additional group of age-matched lean mice receiving the same diet was studied in parallel. Deoxyglucose uptake was measured as a function of insulin concentration in soleus muscles from mice which had been treated for four months (Fig.4) . In muscles from acarbose-treated obese animals, basal glucose uptake, which was significantly (p <0.05) decreased in untreated obese mice, returned to normal. The insulin effect was similarly altered in untreated and treated obese mice both at submaximal and maximal insulin concentrations.
Insulin binding to soleus muscles has been determined with 125I-insulin in the absence (total binding) and in the presence (non-specific-binding) of unlabelled insulin (1 gmol/1) ( 
Effect of acarbose treatment on insulin receptor autophosphorylation and kinase activity
The first step in insulin action following hormone binding to the receptor ~-subunit is the activation of the ~3-subunit tyrosine kinase [25] [26] [27] . This enzymatic property was then studied in partially purified preparations of receptors obtained from lean, untreated and acarbose-treated obese mice. Insulin receptors were incubated with 125I-photoreactive insulin and subsequently submitted to phosphorylation, before immunoprecipitation with normal serum (Fig. 5, lanes A, C, E) or antireceptor antibodies (Fig. 5,  lanes B, D, F) . The autoradiograms clearly show that less phosphorylation of the insulin receptor 13-subunit occurred both in control obese and acarbose-treated obese mice compared with lean mice. This observation was confirmed by measuring the radioactivity present in the two bands: for an equal amount of insulin binding, 22% less radioactivity was found in the ~-subunit of control obese or acarbose-treated obese compared to lean animals. The ability of insulin receptors to catalyse the phosphorylation of an exogenous substrate, a copolymer of glutamate and tyrosine residues in a 4:1 ratio, was then investigated (Fig. 6) . In four different insulin receptor preparations, compared to lean mice preparations where the insulin effect on kinase activity was expressed as 100%, stimulation was found to be 47.2 _+ 5.7% and 47.7 + 2.5%, while insulin binding was 70.7 + 4.3% and 85.3 + 3.2% in control and acarbose-treated obese, respectively (mean + SEM).
Discussion
The results presented in this study show that acarbose treatment partially prevented the development of obesity, hyperglycaemia and hyperinsulinaemia in goldthioglucose obese mice which received a diet enriched with 10% sucrose. Similar to the observations made in db/db mice [14] , food intake was not modified by acarbose. The significantly reduced body weight of the treated-obese animals can therefore be attributed only to the metabolic effects of the drug. Following oc-glycosidase inhibition, the rate of intestinal carbohydrate absorption is reduced [11, 13] and consequently, blood insulin levels are significantly lowered resulting in decreased rates of liver and adipocyte lipogenesis compared to control obese mice. The effect of acarbose in preventing the body weight changes was noticeable only during the first month of treatment. It is possible that the efficacy of the drug was less important after some weeks of treatment since prolonged a-glycosidase inhibition induces significant changes in small intestine disaccharidase activity in treated animals [28] . However, this adaptation is not likely to be very large since lowering effects of acarbose treatment on insulin levels persisted even after three or four months. It should be noted that a small proportion of the mice did not display any beneficial effect of acarbose therapy, since they presented very high insulin levels during the whole study, The lowering effect of acarbose on insulin levels was clearly not sufficient to prevent all the alterations in muscle glucose metabolism. Indeed, when glucose uptake was studied in muscles of mice which had been treated for four months, only basal uptake returned to normal values. Decreased basal (non-insulin-stimulated) glucose uptake has been substantiated in different tissues such as skeletal muscle [3, 5, 6, 18] or adipocytes [7, 29] of obese animals and humans. This alteration is thought to play a major role in the development of hyperglycaemia and insulin resistance. This diminution results, at least in part, from the reduction in the number of glucose transporters [28, 30] . In adipocytes from fasted and refed rats, the number of glucose transporters strongly correlates with the specific mRNA abundance [31] . It is tempting to hypothesize that insulin resistance is also associated with changes in the level of the glucose transporter mRNA and that acarbose is able to prevent both the decrease in transporter mRNA and in glucose transport activity which occurs in obese animals. Clearly, more studies are needed to clarify the mechanism of its action, but this effect of acarbose therapy probably participates in the prevention of hyperglycaemia in obese mice.
Acarbose treatment also partially prevented the decrease in insulin binding, as measured both in intact soleus muscles or in partially purified insulin receptor preparations, a result which was anticipated from the modifications in insulin levels. Scatchard analysis of the data shows that this reflects changes in insulin receptor number (data not shown). However, the magnitude of this effect was not sufficient to prevent insulin resistance in muscle tissue. Indeed, muscle from acarbose-treated mice was still markedly resistant to insulin both at submaximal and maximal effective concentrations. Furthermore, when autophosphorylation of insulin receptors and their tyrosine kinase activity were studied, the alterations were similar in preparations of control obese and acarbose-treated obese mice. Such a defect in the insulin receptor tyrosine kinase activity has also been reported in skeletal muscles and adipocytes of obese Type 2 (non-insulin-dependent) diabetic patients [8, 9, 32, 33] and probably plays a key role in the insulin resistant state. Although the exact mechanism of the alteration of the kinase activity has not yet been determined [17] , it is clear from this study that it does not directly relate to the level of insulin.
In conclusion, this study suggests that acarbose may be of use in reducing the development of obesity and hyperinsulinaemia, in conjunction with high intake of carbohydrates. However, the drug is insufficient to reverse or prevent muscle insulin resistance.
